National Neuromuscular Lecture Series Provides Training Opportunity for Neuromuscular Clinical Fellows
The NMD4C curriculum working group is pleased to share that the inaugural “National Neuromuscular Lecture Series” kicked off this August 12, 2022.
About the Series
This year-long training curriculum for current Canadian neuromuscular fellows has been developed in consultation with the directors of fellowship programs across Canada. The group decided on 41 topics which constitute a comprehensive neuromuscular knowledge base and identified subject-matter experts from across the country to deliver the weekly lectures. The lecture series is designed to offer neuromuscular fellows at Canadian institutions the chance to learn from experts in different disciplines of neuromuscular medicine and forge connections with senior clinicians and investigators from across the country. This lecture series is supplementary to the training and teaching done at each institution.
Format of the Series
The 1-hour lectures are designed with live virtual attendance in mind as the discussion with presenters and colleagues provide valuable experiences. To ensure that all fellows have access to these learning materials, a recording of each lecture is made available on a secure learning platform, which also provides an opportunity to engage in a weekly discussion forum.
To learn more about this lecture series, please contact the curriculum working group lead Dr. Hernan Gonorazky, or NDM4C Communications Coordinator, Lola Owoeye!
Ongoing Neuromuscular Curriculum Work
The launch of this lecture series comes soon after the Royal College of Physicians and Surgeons of Canada’s approval of an Area of Focused Competency in Neuromuscular Medicine, an accreditation that establishes a national standard for training and specialist competence, provides neuromuscular fellows with additional opportunities to acquire nationally and internationally portable credentials, and will help to centralize specialty training, care, and practice by providing credentials in the highly focused area of neuromuscular practice.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.